Innovative Microbiome-based IBD Therapeutics to Be Developed Under New Partnership

Innovative Microbiome-based IBD Therapeutics to Be Developed Under New Partnership
Takeda Pharmaceutical, a Japanese biopharmaceutical company, announced a strategic new collaboration with NuBiyota to develop Microbial Ecosystem Therapeutics, a new form of treatment for patients with gastroenterology disorders who fail to respond to available treatments. The partnership will foster the development of oral microbial products using NuBiyota’s gut microbiome platform. The human gut microbiome consists of the 10 trillion to 100 trillion microbes, primarily bacteria that reside in our gut. Scientists are conducting several studies investigating the role of the gut microbiome in our health. Until now, studies have shown that the microbes naturally residing in our gut can modulate how we resp
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *